A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
Key facts
- Where
- Arvada, Chula Vista, Denver, Houston, Orlando, and Pembroke Pines, United StatesSee the 6 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07541287, who can take part
Where in United States
- ArvadaArvada, United StatesTaking people
- Chula VistaChula Vista, United StatesTaking people
- DenverDenver, United StatesTaking people
- HoustonHouston, United StatesTaking people
- OrlandoOrlando, United StatesTaking people
- Pembroke PinesPembroke Pines, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jade Biosciences, Inc.
- Trial code
- NCT07541287
- Record updated
- 30 October 2026
- Original description
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.Read full original descriptionShow less
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient population.
Inclusion: Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent; eGFR ≥ 30 mL/min/1.73 m2; Biopsy-confirmed primary IgAN; Receiving stable and maximally tolerated doses of either ACEi or ARB as per standard of care (SoC) and applicable guidelines for at least 12 weeks prior to the initial screening visit, with no intention to alter the dose or discontinue treatment, unless medically necessary; UPCR ≥ 0.75 g/g; Willing to provide written informed consent; Willing and able to comply with scheduled study visits, treatment plans, laboratory tests, and other study procedures; Willing and able to comply with contraceptive and lifestyle requirements.
Exclusion: Received bone marrow, hematologic stem cell transplantation, or a solid organ transplant, including kidney; Known or suspected alcohol or drug abuse; Known or suspected coexisting Chronic Kidney Disease (CKD) other than IgAN; Evidence of pathological findings in the kidney biopsy in addition to IgAN (eg, minimal change disease, diabetic kidney disease, membranous nephropathy, focal segmental glomerulosclerosis, or lupus nephritis); hypertensive vascular changes are acceptable; Known or suspected primary or secondary immunodeficiency disorder; Evidence of tuberculosis infection at screening; Any chronic infectious disease; Any acute infectious disease at time of screening; Any clinically significant and/or unstable or uncontrolled medical condition as assessed by the investigator; Malignancy within the past 5 years; nonmelanoma skin cancer and curatively treated cervical carcinoma in situ are allowed; Other protocol-defined inclusion/exclusion criteria may apply; Secondary forms of IgAN; Known or suspected rapidly progressive glomerulonephritis (RPGN).